Compare · ABT vs MSLE
ABT vs MSLE
Side-by-side comparison of Abbott Laboratories (ABT) and Satellos Bioscience Inc. (MSLE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and MSLE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT carries a market cap of $221.65B.
- Over the past year, ABT is down 29.7% and MSLE is down 40.4% - ABT leads by 10.7 points.
- ABT has been more active in the news (8 items in the past 4 weeks vs 3 for MSLE).
- ABT has more recent analyst coverage (25 ratings vs 2 for MSLE).
- Company
- Abbott Laboratories
- Satellos Bioscience Inc.
- Price
- $91.15-1.41%
- $7.08+1.29%
- Market cap
- $221.65B
- -
- 1M return
- -13.05%
- -0.98%
- 1Y return
- -29.66%
- -40.40%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 3
- Recent ratings
- 25
- 2
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026
- SEC Form S-8 filed by Abbott Laboratories
- Abbott Labs downgraded by Daiwa Securities with a new price target
- Abbott Laboratories filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
- New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health
- SEC Form 4 filed by Stratton John G
- SEC Form 4 filed by Roman Michael F
Latest MSLE
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
- Leerink Partners initiated coverage on Satellos Bioscience with a new price target
- SEC Form S-8 filed by Satellos Bioscience Inc.
- SEC Form 40-F filed by Satellos Bioscience Inc.
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
- Cantor Fitzgerald initiated coverage on Satellos Bioscience
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference